Disease Information

General Information of the Disease (ID: DIS00294)

• Name: Pulmonary hypertension
• ICD: ICD-11: BB01

Type(s) of Resistant Mechanism of This Disease

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Andrographolide

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: HOX transcript antisense RNA (HOTAIR) [1]

• Resistant Disease: Pulmonary dysfunction [ICD-11:BB01.1]
• Molecule Alteration: Up-regulation; Expression
• Resistant Drug: Andrographolide
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: HBECs; Bronchus; Homo sapiens (Human); CVCL_0287
• In Vivo Model: Male BALB/c mice CS-exposed model; Mus musculus
• Experiment for Drug Resistance: Annexin V-PI Apoptosis detection; Flow cytometry assay
• Mechanism Description: Andrographolide antagonizes the cigarette smoke-induced epithelial-mesenchymal transition and pulmonary dysfunction through anti-inflammatory inhibiting HOTAIR.

References

• Ref 1: Andrographolide antagonizes the cigarette smoke-induced epithelial-mesenchymal transition and pulmonary dysfunction through anti-inflammatory inhibiting HOTAIRToxicology. 2019 Jun 15;422:84-94. doi: 10.1016/j.tox.2019.05.009. Epub 2019 May 23.